SIRT1 is downregulated in diabetic states.15 Conversely, activation of SIRT1 signalling by intermediate fasting or through pharmacological activation may represent an effective therapeutic strategy to prevent clinical sequelae of diabetes.16,17 Pharmaceutical and nutriceutical strategies targeting SIRT1 have been studied previously; however, with unsatisfying results largely due to limited target specificity and poor bioavailability.18–21. Here, SIRT1 is linked to diabetes mellitus.